China backs Indonesia to become vaccine hub of Southeast Asia
|
Before you start reading this news story, we put in context how it relates to the Islamic economy: Indonesian state-owned Bio Farma is working with Chinese firm Sinovac Biotech on a COVID-19 vaccine. Bio Farma told Salaam Gateway in August that it is eyeing halal certification for the potential vaccine. *Salaam Gateway puts global news in context of the Islamic economy* |
Photo via Bloomberg
Published 11 Oct,2020 via Bloomberg Politics & Policy - China supports Jakarta’s efforts to become the center for vaccine production in Southeast Asia, Indonesia Coordinating Minister for Maritime Affairs and Investments Luhut Pandjaitan said after meeting Chinese Foreign Minister Wang Yi.
Indonesia has the strongest capacity for vaccine production in Southeast Asia, Wang said, according to a statement issued by Pandjaitan after the two held a discussion on Saturday. Wang will support China’s companies to step up cooperation, according to the statement.
Volunteers in Indonesia’s city of Bandung, the capital of West Java province, are already taking part in trials for a vaccine being developed by China’s Sinovac Biotech Ltd. Southeast Asia’s biggest economy is also working on its own inoculation, called the Merah Putih vaccine, as it seeks to ensure there are enough doses for its 270 million population.
The two ministers discussed developing three industrial zones in Indonesia’s Bintan, Batang and Semarang areas, and the participation of Chinese universities in researching herbal medicine in North Sumatra, according to the statement released Sunday. Pandjaitan also asked Wang Yi for China to share its experience in efforts to eradicate poverty.
For more articles like this, please visit us at bloomberg.com
©2020 Bloomberg L.P. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)
DISCLAIMER: This content is provided to us “as is” and unedited by an external third party provider. We cannot attest to or guarantee the accuracy of information provided in this article from the external third party provider. We do not endorse any views or opinions included in this article.
Yudith Ho